Browse the evidence

Following unaccustomed eccentric exercise, females exhibit a blunted satellite cell expansion and inflammatory gene expression (Pax7, CCL2) compared to males, suggesting a delayed or reduced myogenic response.

If you are female, your muscle may not expand its satellite cell pool as aggressively as a male's after intense eccentric exercise (like heavy downhill running or heavy eccentrics). This doesn't mean you can't build muscle, but your initial repair signaling might be different. Focus on consistent training and adequate protein intake, as your body may rely on different mechanisms for repair than males.

Exenatide does not demonstrate superior weight loss compared to placebo in adults with craniopharyngioma-related obesity when both groups receive intensive lifestyle interventions.

For adults with obesity caused by brain tumor treatment (craniopharyngioma), adding exenatide to a strict diet and exercise plan does not lead to significantly more weight loss than the diet and exercise alone. The medication may reduce hunger scores, but it does not translate to superior weight loss outcomes in this specific population.

Exenatide reduces hunger scores in adults with craniopharyngioma-related obesity, although this does not translate to significant weight loss.

Exenatide may help reduce the subjective feeling of hunger in patients with craniopharyngioma-related obesity, but this reduction in hunger does not necessarily lead to greater weight loss compared to lifestyle interventions alone.

GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.

GLP-1 medications work partly by changing how your brain processes food cues before you even eat. By activating specific brain regions (DMH), they signal 'stop' based on anticipation, not just stomach fullness. This cognitive effect helps reduce meal size and frequency, contributing to weight loss beyond just slowing digestion.

GLP-2 receptor activation improves intestinal barrier function and reduces systemic low-grade inflammation in obesity, but does not directly reduce appetite or body weight in humans.

GLP-2 receptor agonists (like teduglutide) are not currently recommended for weight loss in humans because they do not reduce appetite or food intake. However, they may help reduce systemic inflammation by improving gut barrier function, which is a key driver of obesity-related complications. This strategy is best used in combination with other weight-loss interventions (like GLP-1 agonists) rather than as a standalone treatment.

Obesity acts as an independent risk factor for chronic kidney disease progression through direct mechanisms (pro-inflammatory adipocytokines, renal hemodynamic alterations causing glomerular hyperfiltration) and indirect mechanisms (hypertension, type 2 diabetes).

Maintain a healthy weight to protect kidney function. Obesity directly stresses the kidneys through hormonal and blood flow changes, leading to protein leakage and reduced filtration. Weight loss interventions can slow this progression.

Social media promotion and celebrity endorsements of semaglutide (specifically Ozempic/Wegovy) for off-label weight loss directly drive global search interest and subsequent supply shortages, overriding regulatory approval timelines.

Search interest in weight loss drugs like semaglutide is currently driven more by social media trends and celebrity endorsements than by official medical approvals. If you are seeing a surge in interest or shortages, it is likely due to viral media content rather than a change in medical guidelines.

The same mHealth intervention does NOT produce statistically significant reductions in systolic or diastolic blood pressure four years after completion, nor does it significantly reduce the incidence of hypertension, although a non-significant trend toward reduced hypertension risk was observed in high-adherence subgroups.

Do not expect this mobile health program to significantly lower your blood pressure, even if it helps you lose weight. The study showed no significant change in systolic or diastolic blood pressure four years after the intervention. However, the weight loss achieved is still a valuable health outcome, and you should continue to monitor your blood pressure with your healthcare provider.

Co-ingesting protein with carbohydrate during endurance exercise does not improve performance or glycogen resynthesis when carbohydrate recommendations are met.

Do not rely on adding protein to your in-exercise nutrition for performance or glycogen storage. Stick to recommended carbohydrate intakes. Save protein for post-exercise recovery.

Timing of creatine ingestion (pre- vs. post-exercise) does not significantly influence gains in muscle mass or strength compared to resistance training alone.

Take your creatine whenever is most convenient for you. Whether you take it before or after your workout makes no measurable difference to your muscle growth or strength gains. Focus on taking it consistently every day rather than stressing about the exact timing.

SGLT2 inhibitors reduce cardiovascular disease risk and mortality in Type 2 Diabetes patients, but are associated with increased risks of urogenital infections, dehydration, hypotension, osteoporotic fractures, and limb amputation.

SGLT2 inhibitors offer significant cardiovascular benefits but require caution in elderly patients and those with kidney disease due to risks of dehydration, hypotension, and infections. Monitor for signs of these side effects.

Acute exposure to moderate terrestrial altitude (2320 m) does not enhance metabolic stress or anabolic hormonal responses compared to normoxia during hypertrophy-oriented resistance training.

If you are training at moderate altitude (around 2300m), do not expect your muscles to grow faster or your hormones to spike more than they would at sea level, provided you are doing the same resistance training routine. The acute stress response is not enhanced by the altitude itself in this context.

Using velocity loss (VL) thresholds to prescribe or monitor resistance training volume for free-weight back squats is flawed and should not be used because the relationship between velocity loss and repetitions completed to failure lacks stability and predictive validity across sessions.

Do not use velocity loss thresholds to determine how many reps to perform in free-weight back squats. The relationship between how fast you move and how many reps you can do is too unstable from session to session to be useful for programming. Stick to traditional methods like RPE or fixed rep ranges.

Inhibition of HIF1α signaling allows regenerating skeletal muscle myofibers to bypass a neonatal maturation checkpoint, thereby accelerating muscle repair and growth following injury.

This research identifies a biological 'brake' on muscle repair: if HIF1α signaling stays high after an injury, the muscle gets stuck in an immature, small state. Pharmacologically lowering HIF1α (e.g., with PX-478 in mice) or genetically removing it allows the muscle to mature faster and grow larger. For humans, this suggests that strategies to modulate hypoxia signaling or mitochondrial fusion (Mfn2) might accelerate recovery from severe muscle trauma, though no such therapy is currently available for general use.

Current precision nutrition tools based on Polygenic Risk Scores (PRS) have limited predictive power because they often fail to account for gene-environment interactions.

Do not rely solely on genetic testing for dietary advice. Current genetic risk scores are incomplete because they ignore your lifestyle. For accurate precision nutrition, genetic data must be combined with environmental factors like diet and activity.

Fast-food restaurants in the US showed little to no consistent reformulation to reduce sodium and saturated fat content per 1,000 kcal between 2000 and 2013, despite public health recommendations.

Do not assume fast food has become healthier due to voluntary industry changes. While trans fats have decreased, sodium and saturated fat levels in core items like fries and burgers remain high and largely unchanged per calorie. To manage intake, you must actively choose items with lower sodium/saturated fat profiles or limit frequency, as the default options have not significantly improved.

Trans fat content in fast-food French fries declined to undetectable levels between 2006 and 2009 due to the phase-out of partially hydrogenated fats, whereas cheeseburgers remained a major source of trans fat due to natural ruminant fat.

You can likely find trans-fat-free French fries at major chains due to oil changes, but cheeseburgers still contain natural trans fats from beef. If you are strictly avoiding all trans fats, you must account for the natural content in meat products, not just processed oils.

Caloric restriction alone in older adults with sarcopenic obesity leads to significant loss of lean muscle mass and grip strength, worsening sarcopenia.

If you are an older adult with obesity, simply eating less (caloric restriction) without exercise can cause you to lose muscle, not just fat. This makes you weaker and more frail. To avoid this, you must combine dietary changes with resistance exercise and ensure you are eating enough protein.

Short-chain fatty acids (SCFAs) such as acetate and propionate regulate glucose homeostasis primarily by activating the GPCR FFAR2 on enteroendocrine L-cells, stimulating the release of GLP-1, which in turn promotes insulin secretion and improves glucose tolerance.

To leverage the glucose-lowering benefits of short-chain fatty acids, focus on consuming fermentable dietary fibers (like those in oats, legumes, and resistant starches) to feed gut bacteria. These bacteria produce SCFAs (acetate, propionate, butyrate) which activate FFAR2 receptors in your gut. This triggers the release of GLP-1, a hormone that signals your pancreas to release insulin more effectively, thereby improving blood sugar control. This is particularly beneficial if you have insulin resistance or type 2 diabetes.

Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, significantly improves both NASH resolution and fibrosis in patients with stage 2-3 fibrosis.

Resmetirom is a prescription medication for NASH with significant fibrosis that has shown the ability to improve both liver inflammation and scarring in clinical trials. It is not an over-the-counter supplement and requires medical supervision.

Obeticholic acid (OCA) reduces hepatic fibrosis without worsening NASH, but its efficacy is modest and it carries safety concerns leading to FDA rejection.

Obeticholic acid can reduce liver scarring in pre-cirrhotic NASH, but its modest benefits and side effects (itching, liver toxicity) led to FDA rejection, making it a less favorable option.

Pegozafermin, an FGF21 analogue, significantly improves fibrosis and NASH resolution in patients with stage 2-3 fibrosis.

Pegozafermin is an experimental FGF21 analogue that has shown significant improvements in liver scarring and NASH in clinical trials, offering hope for patients with stage 2-3 fibrosis.

Individual demographic and socioeconomic factors explain the majority of spatial clustering in extreme BMI values among adults with diabetes, whereas neighborhood environmental factors (food access, deprivation) explain a significantly smaller portion.

If you are managing diabetes and weight, your personal socioeconomic situation and personal choices are stronger predictors of your BMI clustering than the specific food stores or walkability of your immediate neighborhood. While improving neighborhood access is good, focusing on individual-level factors (income, education, personal habits) is likely to have a larger impact on your weight status than relying solely on environmental changes.

Controlled caloric excess (1.4x maintenance) for 8 weeks in healthy adults causes significant increases in visceral adipose tissue, systemic inflammation, insulin resistance, and functional cardiovascular risk markers (abnormal circadian blood pressure variability and endothelial dysfunction).

If you are healthy and maintain your weight, eating 40% more than you need for just two months will still damage your blood vessel function and increase blood pressure variability. You do not need to be overweight to suffer these early cardiovascular risks from overeating.